US Liquid Biopsy Market (By Biomarker Types: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular Vesicles (EVS), Other Biomarkers; By Application: Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application; By Sample: Blood Sample, Urine Sample, other; By End User: Hospitals and Laboratories, Academic and Research Centers, other End Users)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

According to Nova one advisor, the U.S Liquid Biopsy Market Size was valued at USD 362.92 million in 2022 and is predicted to be worth USD 1,817.15 million by 2032, with a CAGR of 17.60% from 2023 to 2032. 

Key Takeaways:

• On the basis of biomarker types, the circulating tumor cells (CTC) segment is anticipated to dominate the market from 2023 to 2032.
• On the basis of application, the cancer therapeutic application segment had the major market share in 2021.
• On the basis of the sample, the blood sample segment is predicted to expand at the biggest rate from 2023 to 2032.
• On the basis of end-user, the hospitals and laboratories segment had the major market share in 2021.

A technique that involves diagnosing and tracking diseases like cancer is known as liquid biopsy. This technique involves sampling and analyzing biological tissues in a liquid condition. Liquid biopsies are mainly preferred to eliminate the discomfort associated with operations. For instance, blood and urine are the liquid samples utilized in the method. Both of these samples are obtained painlessly and readily. It is mainly a practical application of two developments in medical science, human genome sequencing and the growing sensitivity of detection measures and assays. Additionally, it provides a risk-free and efficient option for patients who are unable to have a tissue biopsy due to the risks associated, such as those with lung cancer who have tumors that are too close to the heart. Clinical utility challenges, lack of sensitivity, and specificity of liquid biopsy tests are some of the key factors hindering the growth of liquid biopsy.

Report Scope of the U.S Liquid Biopsy Market

Segments Insight

Biomarker Type Insights

Based on the biomarker type, the U.S. Liquid Biopsy Market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (CTDNA), extracellular vesicles (EVs), and other biomarkers. Due to the increased global cancer prevalence, the Circulating Tumor Cells(CTC) category is anticipated to dominate the liquid biopsy market over the forecast period. The cells that break out from primary or secondary cancers and enter the bloodstream are known as Circulating Tumor Cells. The predictive and prognostic biomarkers in various cancers, including lungs, breast, and prostate, are CTC. Additionally, the circulating tumor DNA segment is expected to grow significantly during the forecast period.

Sample Insights

Based on the sample, the U.S. Liquid Biopsy Market is segmented into blood samples, urine samples, and others. The Blood sample category is expected to expand at the fastest rate over the review period. A blood test is painless and has no risks, along with this, it cuts down cost and time to diagnose a problem. Blood-based liquid biopsy is popular as it can detect CTCs, cfDNAs, exosomes, and microvesicles.

Additionally, the urine sample segment is expected to grow significantly over the forecast period.  The urine-based sample collection has various advantages over blood sample collection including increased patient compliance for cancer screening and the ability to monitor patients more frequently. 

Application Insights

Based on the application, the U.S. Liquid Biopsy Market is segmented into cancer therapeutic applications, reproductive health, and other therapeutic application. The cancer application category had the most market share in 2021. The growing prevalence of cancer and the increase in research studies on liquid biopsy for cancer applications are driving the growth of this market. A type of test that can be used for cancer screening at an early stage is a liquid biopsy. It can be used to determine how well the treatment is working and whether the cancer has returned. The ctDNA tests may be able to detect more cancers at an early stage, which reduces the risk of death from that cancer.

End-User Insights

Based on the end-user, the U.S. Liquid Biopsy Market is segmented into hospitals and laboratories, academic and research centers, and other end users. The laboratories market category had the most market share in 2021. The increased outsourcing of liquid biopsy testing to reference labs is driving the growth of this industry. The revenue growth of hospitals is mainly driven by the emergence of cancer specialty hospitals in developing countries with the availability of advanced procedures, such as liquid biopsy.

Some of the prominent players in the U.S Liquid Biopsy Market include:

• ANGLE plc, Biocept Inc.
• Bio-Rad Laboratories Inc.
• Epigenomics AG
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc. 
• Illumina Inc.
• MDxHealth SA 
• Menarini Silicon Biosystems
• QIAGEN N.V. 
• Thermo Fisher Scientific Inc.

Segments Covered in the Report

This report forecasts revenue growth and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S Liquid Biopsy market.

By Biomarker Types 

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (CTDNA)
• Extracellular vesicles (EVS)
• Other Biomarkers

By Application 

• Cancer Therapeutic Application
• Reproductive Health
• Other Therapeutic Application

By Sample 

• Blood Sample
• Urine Sample 
• Other

By End User 

• Hospitals and Laboratories
• Academic and Research Centers
• Other End Users